Review anchor
Serine/threonine-protein kinase Nek1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Serine/threonine-protein kinase Nek1
CHEMBL5855
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Serine/threonine-protein kinase Nek1 as ChEMBL target CHEMBL5855, mapped to UniProt Q96PY6. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL5855
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q96PY6
Serine/threonine-protein kinase Nek1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Serine/threonine-protein kinase Nek1 matters
Serine/threonine-protein kinase Nek1 is reviewed as Serine/threonine-protein kinase Nek1 (UniProt Q96PY6); the current evidence base includes 2 approved drugs, 1373 compounds, and 284 assays, with lead potency reaching pChEMBL 9.4.
Protein context
Serine/threonine-protein kinase Nek1
Serine/threonine-protein kinase Nek1 Sequence length is 1258 aa.
Review this target as Serine/threonine-protein kinase Nek1, mapped to UniProt Q96PY6. Sequence length is 1258 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q96PY6
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 2 approved drugs, 1373 compounds, and 284 assays for this target. The dominant activity type is KD. CHEMBL3667204 is the current potency anchor at pChEMBL 9.4.
Use CHEMBL3667204 as the tractability anchor when discussing potency (pChEMBL 9.4).
Activity source · ChEMBL 36 via Core Engine
2 approved
pChEMBL 9.4
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Serine/threonine-protein kinase Nek1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q96PY6, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1373
Total Compounds
284
Total Assays
2
Approved Drugs
IC50: 290.0, KI: 4.0, KD: 372.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3667204
|
9.4 | IC50 | — |
|
|
No preferred name
CHEMBL3667261
|
9.4 | IC50 | — |
|
|
No preferred name
CHEMBL3667249
|
9.3 | IC50 | — |
|
|
No preferred name
CHEMBL3667248
|
9.3 | IC50 | — |
|
|
No preferred name
CHEMBL3667234
|
9.2 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
DABRAFENIB
CHEMBL2028663
|
2013 |
Source Header